Spark Biomedical Completes Enrollment in a Neurostimulation Pivotal Trial for Opioid Use DisorderFinal enrollment concludes for Spark Biomedical's pivotal study investigating a non-invasive, drug-free neurostimulation therapy aimed at improving treatment retention for adults with opioid use disorder.
Spark Biomedical Secures $15M Series A To Advance Drug-Free Wearable Neurostimulation TherapiesThe investment will support the company’s core areas of bioelectronic medicine, including neurological health, hemostasis, and women’s health.
Spark Biomedical Completes Enrollment for Pivotal Trial in Neonatal Opioid Withdrawal TreatmentClinical enrollment concludes for Spark Biomedical’s pivotal trial investigating a non-invasive, drug-free neurostimulation treatment for newborns born with NOWS.
Spark Biomedical Partners With Air Force To Launch Trial Testing Innovative Solution to Motion Sickness and Spatial DisorientationThis trial will test the feasibility of wearable neurostimulation to help reduce fatal disorientation-related errors in the military.
Spark Biomedical Sets Sights on Global Expansion with New ISO 13485 and MDSAP Certifications2024 audits of ISO 13485 from DEKRA confirm Spark Biomedical meets international standards for quality management systems.
Spark Biomedical Launches New Academic Research Fellowship Program Focused on Medical Device EntrepreneurshipSpark Biomedical launches a unique fellowship program that enables neurosurgery residents to collaborate with medical device industry leaders advancing technology and shaping the future of healthcare.
Spark Biomedical Awarded National Institute on Drug Abuse Funding to Develop AI-Algorithm for Opioid Withdrawal and Cravings DetectionSpark Biomedical is joined by the Battelle Memorial Institute and Hazelden Betty Ford Foundation to begin pioneering an AI-powered, wearable, closed-loop neurostimulation system to improve opioid withdrawal treatment retention and reduce relapse and overdose rates.
Spark Biomedical Introduces Sparrow Link: A Revolutionary Research Platform for Non-Invasive NeurostimulationSpark Biomedical unveils the Sparrow® Link Research Platform designed to enable research teams to customize the transcutaneous auricular neurostimulation (tAN) power of the FDA-cleared Sparrow Ascent.
Spark Biomedical Has Been Issued New CMS Codes for Transcutaneous Auricular Neurostimulation (tAN®) Therapy via Sparrow AscentThe Centers for Medicare and Medicaid Services codes will help increase accessibility to wearable bioelectric medicine for opioid withdrawal.
Behind the Scenes of Medical Innovation: Spark Biomedical launches new web series ‘Spark a Conversation’From concept to cure, Spark a Conversation dives into the development of a revolutionary approach to opioid withdrawal symptom treatment.
Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal TreatmentDALLAS, TX, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in AdultsThis FDA-cleared wearable neuromodulation system offers game-changing access for patients to start the road to recovery without interruptions to daily living
Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand DiseaseWearable auricular neurostimulation device could offer a novel treatment option for the most common inherited bleeding disorder.
Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawalCollaborative study awarded to the University of Texas Medical Branch, Medical University of South Carolina, and Spark Biomedical
